Neumora Therapeutics, Inc. Common Stock (NMRA)의 가격은 얼마입니까?

Neumora Therapeutics, Inc. Common Stock (NMRA)의 가격은 $1.33입니다.

Neumora Therapeutics, Inc. Common Stock (NMRA)의 시가 총액은 무엇입니까?

Neumora Therapeutics, Inc. Common Stock (NMRA)의 시가 총액은 $246.43M입니다.

Neumora Therapeutics, Inc. Common Stock (NMRA) 가격 이력

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

연도	성과
2026 (TTM)	4.72%
2025	-81.20%
2024	-26.84%
2023	0.00%

연도

성과

2026 (TTM)

4.72%

2025

-81.20%

2024

-26.84%

2023

0.00%

회사	주가	변동률 1년%	국가
Vertex Pharmaceuticals Incorporated VRTX.US	$554.82	38.36%	US
Argenx SE ARGX.US	$1.05K	48.67%	NL
Moderna, Inc. MRNA.US	$148.77	515.03%	US
CSL Limited CSL.AX	$122.21	-10.03%	AU
Lonza Group AG LONN.SW	$762.39	8.87%	CH

회사

주가

변동률 1년%

국가